Drug Profile
Research programme: CETP inhibitors - Eli Lilly and Company
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 24 Mar 2009 Preclinical development is ongoing in USA
- 20 Apr 2007 Preclinical trials in Atherosclerosis in USA (unspecified route)